General Atlantic agreed to invest $100m in Chi-Med, an innovative biopharmaceutical company. The proceeds will fund ongoing research and clinical development and support the further growth of its commercialization capabilities both in China and globally. “Over the last few months, we have made significant development, regulatory and commercial progress in several oncology programs intended for the global market. We are delighted therefore to welcome General Atlantic to our existing shareholder base and to further strengthen our balance sheet. We are confident that in this phase of material progress for Chi-Med we can deliver innovative cancer therapies to patients internationally,” Christian Hogg, Chi-Med CEO.